Case Report · Kasuistik
Intraperitoneal Catumaxomab Therapy in a Cirrhotic Patient with Malignant Ascites due to Urethelial Carcinoma: A Case ReportKrawczyk M. · Zimmermann S. · Vidacek D. · Lammert F.
Department of Medicine II, Saarland University Medical Center, Homburg, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Refractory malignant ascites is a common complication in tumor patients. To date, chemotherapy and paracentesis represent the most widely used methods to relieve the symptoms. Lately, intraperitoneal therapy with catumaxomab, a trifunctional hybrid antibody, has been introduced for the treatment of malignant ascites, and its utility has been demonstrated in patients with distinct abdominal malignancies. Case Report: We report the first case of successful catumaxomab treatment of malignant ascites in a patient with advanced carcinoma of the urinary bladder and liver cirrhosis. Although at admission a largevolume paracentesis was needed every other day, paracentesis was no longer necessary after catumaxomab therapy. Conclusion: Catumaxomab might represent a safe treatment option for malignant ascites in the course of metastatic urothelial carcinoma, also in the setting of liver cirrhosis.
© 2012 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.